WebDisclosure WebDisclosure
Basculer en Français
9763 Companies
195283 Keywords
126291 Articles
103826 Press releases
Headlines Articles Press releases Generate:Biomedicines Remove
  1. Home
  2. Companies
  3. Generate:Biomedicines
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 12/01/2025 at 12:10, 1 month 27 days ago

    Generate:Biomedicines Initiates Phase 3 Trials for Asthma Antibody GB-0895

    Phase 3 Trials Generate:Biomedicines GB-0895 Asthma Treatment AI Engineered Antibody
  • BRIEF

    published on 12/01/2025 at 12:10, 1 month 27 days ago

    Generate:Biomedicines lance des essais de phase 3 pour l'anticorps contre l'asthme GB-0895

    Essais De Phase 3 GB-0895 Générer : Biomédicaments Traitement De L'asthme Anticorps Conçu Par IA
  • PRESS RELEASE

    published on 12/01/2025 at 12:05, 1 month 27 days ago

    Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

    Generate:Biomedicines to initiate global Phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI. SOLAIRIA-1 and SOLAIRIA-2 will evaluate efficacy in reducing asthma exacerbations, reflecting commitment to developing innovative therapies
    AI Engineering Phase 3 Studies Generate:Biomedicines GB-0895 Severe Asthma
    Logo of Generate:Biomedicines
Accesswire
  • Published on 01/29/2026 at 03:30, 3 hours 54 minutes ago

    NuRAN Provides Clarification and Corrections Regarding Restructuring Transaction Disclosure

  • Published on 01/29/2026 at 02:15, 5 hours 9 minutes ago

    McEwen Inc. to Acquire Golden Lake Exploration Inc.

  • Published on 01/29/2026 at 01:50, 5 hours 34 minutes ago

    Alphinat Annonce Un Bénéfice Net De 89 282 $ Pour L'exercice Terminé Le 30 Novembre 2025

  • Published on 01/29/2026 at 01:50, 5 hours 34 minutes ago

    Alphinat Announces a Net Profit of $89,282 for Quarter Ended November 30, 2025

  • Published on 01/29/2026 at 00:00, 7 hours 24 minutes ago

    Tokenwell Adds Single-Coin Trading Capabilities and Expands Exchange Support

View all ACCESSWIRE
EQS Group
  • Published on 01/29/2026 at 07:00, 23 minutes ago

    Nemetschek Group closes a very successful fiscal year 2025 with strong performance and well achieving both its already previously raised revenue forecast and its profitability target

  • Published on 01/29/2026 at 07:00, 23 minutes ago

    Resignation of Philomena Colatrella from the Swiss Life Board of Directors

  • Published on 01/29/2026 at 07:00, 23 minutes ago

    Philomena Colatrella quitte le conseil d’administration de Swiss Life

  • Published on 01/29/2026 at 07:00, 24 minutes ago

    ABB completes 2025 share buyback program

  • Published on 01/29/2026 at 07:00, 24 minutes ago

    Changes to the Board of Directors: Annelis Lüscher Hämmerli and Urs Simeon nominated for election

View all EQS
Les Echos
  • Published on 01/28/2026 at 18:00, 13 hours 24 minutes ago

    Launch of Skira Education Systems and acquisition of Institut Beau Cèdre

  • Published on 01/28/2026 at 18:00, 13 hours 24 minutes ago

    Lancement de Skira Education Systems et acquisition de l'Institut Beau Cèdre

  • Published on 01/28/2026 at 18:00, 13 hours 24 minutes ago

    ALPOU - Groupe POULAILLON - Résultats annuels consolidés au 30 septembre 2025

  • Published on 01/28/2026 at 17:46, 13 hours 38 minutes ago

    250128_PR_Revenue_Q4_2025_EN

  • Published on 01/28/2026 at 17:46, 13 hours 38 minutes ago

    250128_CP_CA_T4_2025_FR

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy